Since the beginning of the Public Health Emergency (PHE), manufacturers have been developing monoclonal antibodies (mAbs) and other treatment modalities to prevent and treat COVID-19.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept